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Receptor-binding residues lie in central regions of Duffy-binding–like domains
involved in red cell invasion and cytoadherence by malaria parasites
Alfredo Mayor, Nivedita Bir, Ritica Sawhney, Shailja Singh, Priyabrata Pattnaik, Saurabh Kumar Singh, Amit Sharma, and Chetan E. Chitnis
Erythrocyte invasion by malaria parasites
and cytoadherence of Plasmodium falcip-
arum-infected erythrocytes to host capil-
laries are 2 key pathogenic mechanisms
in malaria. The receptor-binding domains
of erythrocyte-binding proteins (EBPs)
such as Plasmodium falciparum EBA-
175, which mediate invasion, and P falcip-
arum erythrocyte membrane protein 1
(PfEMP-1) family members, which are en-
coded by var genes and mediate cytoad-
herence, have been mapped to conserved
cysteine-rich domains referred to as
Duffy-binding–like (DBL) domains. Here,
we have mapped regions within DBL do-
mains from EBPs and PfEMP-1 that con-
tain receptor-binding residues. Using bio-
chemical and molecular methods we
demonstrate that the receptor-binding
residues of parasite ligands that bind
sialic acid on glycophorin A for invasion
as well as complement receptor-1 and
chondroitin sulfate A for cytoadherence
map to central regions of DBL domains.
In contrast, binding to intercellular adhe-
sion molecule 1 (ICAM-1) requires both
the central and terminal regions of
DBLC2 domains. Determination of func-
tional regions within DBL domains is the
first step toward understanding the struc-
ture-function bases for their interaction
with diverse host receptors. (Blood. 2005;
105:2557-2563)
© 2005 by The American Society of Hematology
Introduction
The clinical symptoms of malaria are attributed to the blood stage
of the malaria parasite’s life cycle. The invasion of erythrocytes by
malaria parasites is, thus, key to malaria pathogenesis. Of the 4
Plasmodium species that cause human malaria, Plasmodium fal-
ciparum is responsible for the vast majority of deaths resulting
from malaria. The virulence of cerebral and other forms of severe
malaria is mainly due to the sequestration of infected erythrocytes
containing P falciparum trophozoites and schizonts in the vascula-
ture of diverse host organs.1 Sequestration of P falciparum in brain
capillaries is implicated in the pathologic outcome of cerebral
malaria.2-4 In case of infection during pregnancy, P falciparum late
stages may sequester in the placenta, resulting in complications that
often put the lives of both mother and child at risk.5 Erythrocytes
infected with P falciparum can also bind uninfected erythrocytes to
form rosettes, a cytoadherence phenotype that is also associated
with severe malaria.6 It is important to understand the molecular
interactions between malaria parasites and the host that mediate red
cell invasion and cytoadherence, 2 important pathogenic mecha-
nisms in malaria.
A family of erythrocyte-binding proteins (EBPs) mediates
interactions with erythrocyte receptors during invasion.1,7 The EBP
family includes Plasmodium vivax and Plasmodium knowlesi
Duffy-binding proteins (PvDBP and PkDBP), P knowlesi  and 
proteins that bind receptors other than Duffy antigen on rhesus
erythrocytes, and the 175-kDa erythrocyte-binding antigen from P
falciparum (EBA-175), which binds sialic acid residues on glyco-
phorin A.7 The functional receptor-binding domains of EBPs have
been mapped to their N-terminal, conserved, cysteine-rich regions
that are referred to as region II.8,9 These functional receptor-binding
domains are also referred to as Duffy-binding–like (DBL) domains
after the first erythrocyte-binding domain identified from PvDBP
and PkDBP.8 DBL domains are also found in the P falciparum
erythrocyte membrane protein 1 (PfEMP-1) family of variant
surface antigens, which are expressed on the surface of P falciparum-
infected erythrocytes and bind endothelial receptors to mediate
cytoadherence.10-12 Binding domains for endothelial cytoadherence
receptors such as intercellular adhesion molecule 1 (ICAM-1),
CD31, chondroitin sulfate A (CSA), heparan sulfate, complement
receptor 1 (CR1), and immunoglobulin G (IgG) have been mapped
to DBL domains of PfEMP-1.13-22
Malaria parasites thus use DBL domains to mediate diverse
receptor-ligand interactions that are involved in both red cell
invasion and cytoadherence. It is important to understand the
structure-function basis for the interaction of DBL domains with
the diverse host receptors that they bind to. As a first step in this
direction, it is important to map receptor-binding sites within DBL
domains. Regions II, the binding domains of PvDBP and PkDBP,
which are also referred to as PvRII and PkRII respectively,
contain about 350 amino acids including 12 cysteines.23,24 The
binding residues for the Duffy antigen map to the central approxi-
mately 170-amino acid stretch of PvRII and PkRII that includes
cysteines C5 to C8 (Figure 1).24 Here, we demonstrate that the
binding residues of other DBL domains derived from EBPs and
PfEMP-1 that bind diverse host receptors such as sialic acid
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residues on glycophorin A, CR1, and CSA also map to central
regions that are equivalent to the C5 to C8 stretch of PvRII and
PkRII. An exception is a DBLC2 domain from PfEMP-1 that
binds ICAM-1, which requires sequences from both the central
region of the DBL domain as well as sequences from the
adjoining C2 region for binding. Understanding the structure-
function bases for the interaction of DBL domains with their
receptors may allow the development of novel methods to block
red cell invasion and cytoadherence and provide protection
against malaria.
Materials and methods
Production of recombinant F2, the binding domain of P
falciparum EBA-175
Plasmid pF2PET1, which contains a DNA fragment that encodes the F2
domain of EBA-175 (amino acids 447-795 of EBA-175) fused with a
C-terminal 6-histidine tag cloned downstream of the T7 promoter in the
Escherichia coli expression vector pET28a (Novagen, Madison, WI), was
used for expression of recombinant F2 in E coli BL21(DE3) cells
(Novagen) as previously described.25 Recombinant F2 was purified from
inclusion bodies under denaturing conditions by metal affinity chromatogra-
phy, refolded by the method of rapid dilution, and purified to homogeneity
by ion-exchange chromatography using SP-Sepharose and gel filtration
chromatography using Superdex 75 as previously described.25
Proteolysis of recombinant F2 and pull-down assays to test
binding to glycophorin A
Chymotrypsin was used for mild proteolysis of bacterially expressed and
refolded recombinant F2 domain of P falciparum EBA-175. Recombinant
F2 (5 g) was digested with 0.4 g chymotrypsin (Sigma, St Louis, MO) in
10 L cleavage buffer (50 mM Tris [tris(hydroxymethyl)aminomethane]–
HCl, pH 7.5, 100 mM NaCl, and 0.02% sodium azide) for either 1 hour
(incomplete proteolysis) or 2 hours (complete proteolysis) at 21°C. The
reaction was stopped by addition of 1 mM phenylmethylsulfonyl fluoride
(PMSF). Full-length F2 and proteolytic fragments of F2 were incubated
with 5 g purified glycophorin A (Sigma) at 4°C for 1 hour to allow binding
followed by incubation for another 1 hour at 4°C with anti–glycophorin A
mouse monoclonal antibodies (Sigma) at 1:100 dilution. The mixture was
incubated with 50% slurry of protein A beads (Pharmacia, Uppsala,
Sweden) for 1 hour at 4°C. Protein A beads with bound protein-antibody
complexes were separated by centrifugation for 10 minutes at 1500g at 4°C.
The beads were boiled for 15 minutes in presence of nonreducing sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer and centrifuged at 1500g for 20 minutes at 4°C. Released proteins in
the supernatant were separated by SDS-PAGE, transferred to Immuno-Blot
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA), and
detected using rabbit sera raised against recombinant F2.25 The identity of
F2 fragments transferred to PVDF membranes was determined by protein
N-terminal amino acid sequencing at a commercial facility at Michigan
State University (East Lansing, MI). In control experiments, recombinant
F2 was incubated with 1% bovine serum albumin (BSA) instead of
glycophorin A prior to addition of anti–glycophorin A antibodies in
pull-down assays. Recombinant PvRII, the binding domain of PvDBP, was
produced as described earlier26 and used in pull-down assays with
glycophorin A as another negative control. Rabbit serum raised against
recombinant PvRII was used to detect PvRII by Western blotting in control
pull-down assays.
Constructs for expression of full-length, deletion, and chimeric
DBL constructs on the surface of mammalian cells
Plasmids were constructed to express DBL domains derived from EBPs and
PfEMP-1 on the surface of mammalian cells as described earlier.8 Briefly,
DBL domains were fused to the signal sequence and transmembrane
domain of herpes simplex virus glycoprotein D (HSV gD) to allow targeting
to the mammalian cell surface.8,27 The plasmid pRE4 (kindly provided by
Drs Roselyn Eisenberg and Gary Cohen, University of Pennsylvania,
Philadelphia), which contains the gene for HSV gD, was digested with
PvuII and ApaI to excise the central region encoding amino acids 33 to 248
of HSV gD.8,27 DNA fragments encoding full-length or truncated DBL
domains were amplified by polymerase chain reaction (PCR) using
Pyrococcus furiosus DNA polymerase-specific primers (Strategene, La
Jolla, CA), based on DBL domain sequences and plasmids containing the
DBL domains as templates. PCR products were digested with PvuII and
ApaI and cloned in the vector pRE4. Chimeric constructs containing DNA
fragments from different DBL domains were made as described previ-
ously.23 Table 1 describes the boundaries and primers used to make
constructs in the pRE4 vector to express full-length, truncated, and chimeric
DBL domains on the surface of mammalian cells.
Mammalian cell culture, transfection, and immunofluorescence
assays
COS-7 and 293T cells were cultured in Dulbecco modified Eagle medium
(DMEM; Invitrogen, Carlsbad, CA) with 10% heat-inactivated fetal calf
serum (FCS) in a humidified CO2 (5%) incubator at 37°C. Fresh monolay-
ers of 40% to 60% confluent COS-7 and 293T cells growing in 35-mm
diameter wells were transfected with 2 to 4 g plasmid DNA using
Lipofectamine Plus reagent (Invitrogen) as described by the manufacturer.
Transfected cells were used for immunofluorescence and binding assays 36
to 40 hours after transfection. Immunofluorescence assays using mouse
monoclonal antibody DL6 (kindly provided by Drs Roselyn Eisenberg and
Gary Cohen), which reacts with amino acids 272 to 279 of HSV gD, were
performed as described earlier8,27 to detect expression of the fusion proteins
on the surface of transfected COS-7 and 293T cells.
Erythrocyte-binding assays with COS-7 cells expressing DBL
domain fragments on the surface
Transfected COS-7 cells expressing various deletion constructs of
EBA175-F2 and R29-DBL were tested for binding to erythrocytes as
described previously.8 Transfected COS-7 cells expressing F2 constructs
were tested for binding to normal, neuraminidase-treated, and trypsin-
treated human erythrocytes. Erythrocytes were treated with neuraminidase
and trypsin as described previously.9,23 Transfected COS-7 cells expressing
R29-DBL constructs were tested for binding to normal human erythro-
cytes and CR1-deficient erythrocytes (kindly provided by Dr Karina
Yazdanbaksh, New York Blood Centre [NYBC], New York, NY). The copy
number of CR1 on CR1-deficient erythrocytes was about 10% of normal
levels (personal communication, Dr Karina Yazdanbaksh, January 13,
2004). The number of rosettes of erythrocytes bound to transfected COS-7
Figure 1. DBL domains from EBPs and PfEMP-1. Shown are the DBL domains
including the binding domains of PvDBP and PkDBP (PvRII and PkRII); the binding
domain of EBA-175 (F2), which binds sialic acid on glycophorin A; the DBL domain
of R29var1, which binds CR1; the DBL domain of FCR3varCSA, which binds CSA;
and the DBLC2 domain of JDP8ICAMvar, which binds ICAM-1. The position of
chymotrypsin cleavage of F2 between tyrosine 531 (531Y) and lysine 532 (532K), which
results in the 24-kDa F2 fragment that retains binding activity is shown. Shaded
regions show the minimal deletion construct for each DBL domain that retains binding
activity. Sticks under the domains show positions of cysteines. Sticks with black dots
indicate cysteines that are included in the minimal functional deletion construct for
each domain. The receptors the domains bind to are shown on the right; aa indicates
amino acid.
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cells was scored in 25 fields at  200 magnification. A cluster of 6 or more
erythrocytes bound to a COS-7 cell was scored as a rosette.
Binding of CSA to 293T cells expressing full-length or
truncated FCR3-DBL domain on the surface
Mammalian 293T cells were grown on coverslips and transfected with
constructs designed to express full-length or truncated FCR3-DBL
domains on the surface. Coverslips with transfected 293T cells were
transferred to 12-well culture plates 36 to 40 hours after transfection and
used to test binding of CSA as described earlier.21 Briefly, cells were
washed once with phosphate-buffered saline (PBS) and fixed with 2%
paraformaldehyde. CSA, CSB, and CSC (Calbiochem, San Diego, CA)
were biotinylated using a biotinylation kit (Pierce, Rockford, IL) as
described by the manufacturer. Transfected 293T cells were incubated
with biotinylated CSA (Bio-CSA), Bio-CSB, or Bio-CSC (100 g/mL)
for 1 hour at room temperature, washed 3 times with PBS, and incubated
with mouse sera (1:200 dilution) raised against biotin (Sigma). Cells
were washed 3 times with PBS and incubated with fluorescein-
isothiocyanate (FITC)–conjugated anti–mouse IgG goat antibodies
(Sigma) diluted 1:200. Cells were washed 3 times with PBS and
mounted with coverslips after addition of Antifade reagent (Sigma). All
sera were diluted in PBS containing 0.5% BSA (Sigma) and all
incubations with antibodies were for 1 hour at room temperature.
Number of fluorescent and total cells was scored in 15 fields at  1000
magnification to determine the binding efficiency.
Binding of ICAM-1 to COS-7 cells expressing full-length,
truncated, and chimeric DBLC2 domain fragments
ICAM1-Fc was purified from supernatants of transfected COS-7 cells by
affinity chromatography on protein G columns and used for binding assays
as previously described.19,22 ICAM1-Fc was coated on Dynal magnetic
beads and tested for binding to transfected COS-7 cells expressing
DBLC2 constructs on the surface as described earlier.19,22
Results
Binding residues for sialic acids on glycophorin A lie between
cysteines 5 and 9 of EBA-175 DBL domain F2
EBA-175 binds sialic acids on glycophorin A to mediate invasion
of human erythrocytes by P falciparum merozoites.28 The extracel-
lular domain of EBA-175 contains tandem repeated DBL domains,
F1 and F2, within the N-terminal cysteine-rich region, region II.9,29
The receptor-binding domain of EBA-175 maps to DBL domain
F2, which contains 14 cysteines9 (Figure 1). Recombinant F2
was expressed in E coli, extracted from inclusion bodies,
refolded by the method of rapid dilution, and purified to
homogeneity as described previously.25 Refolded F2 migrates on
SDS-PAGE as a single band of about 42 kDa and binds normal
human erythrocytes but not neuraminidase-treated erythrocytes
Table 1. Constructs used for expression of full-length, truncated, and chimeric DBL domains on surface of mammalian cells
Construct Description PCR primers*
EBA175-F2(C1-C14) AA 447-795 of EBA-175 F: 5 acaagtcagctggaaaagcgtgaacatattgat 3
R: 5 tctcgtgggcccatcgtcatcacgttctttttg 3
EBA175-F2(C5-C14) AA 505-795 of EBA-175 F: 5 acaagtcagctgggaaacattgatagaatatac 3
R: 5 tctcgtgggcccatcgtcatcacgttctttttg 3
EBA175-F2(C5-C12) AA 505-736 of EBA-175 F: 5 acaagtcagctgggaaacattgatagaatatac 3
R: 5 tctcgtgggccctttataatctgaatctaattc 3
EBA175-F2(C5-C9) AA 505-639 of EBA-175 F: 5 acaagtcagctgggaaacattgatagaatatac 3
R: 5 tctcgtgggcccatcttcacaaggtttttcttt 3
R29-DBL(C1-C14) AA 82-391 of R29var1 F: 5 tctcgtcagctggagtacaccgaaggtagaaag 3
R: 5 acgagtgggccctttccttttttgcttatcaaattgttttc 3
R29-DBL(C5-C12) AA 133-366 of R29var1 F: 5 tctcgtcagctggatagaaatttagaatatttgatc 3
R: 5 acgagtgggcccacgtggacaatttaaatctataaag 3
FCR3-DBL(C1-C10) AA 1270-1578 of FCR3varCSA F: 5 acttgccagctggaaaacgatggaaagaaac 3
R: 5 acgagtgggccccctgttcaagtaatctgttg 3
FCR3-DBL(C5-C10) AA 1315-1527 of FCR3varCSA F: 5 acttgccagctggtacatttcttggcaaatg 3
R: 5 acgagtgggcccttctgtatcacacttcaattg 3
FCR3-DBL(C5-C8) AA 1315-1517 of FCR3varCSA F: 5 acttgccagctggtacatttcttggcaaatg 3
R: 5 acgagtgggccctttaacgtagtcctcgcatttc 3
JDP8-DBLC2(C1-C16) AA 853-1275 of JDP8Icvar F: 5 tctcgtcagctgaacaatattccaatgct 3
R: 5 acgagtgggcccctcgactttgccgccatc 3
FCR3-DBLC2(C1-C16) AA 810-1260 of FCR3varCSA F: 5 tctcgtcagctgataaaacattctaatcgtaatctt g 3
R: 5 acgagtgggcccttccgtatccttttcttccgc 3
CH1 AA 853-1141 (DBL) of JDP8Icvar fused to AA 1125-1260 (C2) of FCR3varCSA F1: 5 tctcgtcagctgaacaatattccaatgct 3
R1: 5 gtatttcagttccattttgctcc 3
F2: 5 aaagaattacatgaacaagcac 3
R2: 5 acgagtgggcccttccgtatccttttcttccgc 3
CH2 AA 810-1130 (DBL) of FCR3varCSA fused to AA 1128-1275 (C2) of JDP8Icvar F1: 5 tctcgtcagctgataaaacattctaatcgtaatcttg 3
R1: 5 gtatttatctgatattatattccattg 3
F2: 5 tgtacttcgaatttggaac 3
R2: 5 acgagtgggcccctcgactttgccgccatc 3
JDP8-DBLC2(C3-C16) AA 905-1275 of JDP8Icvar F: 5 tctcgtcagctgacttcgaatttggaacatttac 3
R: 5 acgagtgggcccctcgactttgccgccatc 3
JDP8-DBL(C3-C7) AA 905-1098 of JDP8Icvar F: 5 tctcgtcagctgacttcgaatttggaacattta 3
R: 5 acgagtgggcccaataccacactgcgtctc 3
AA indicates amino acid.
*Forward (F) and reverse (R) primers used for amplification of DNA encoding DBL domain fragments by PCR are shown.
Two pairs of primers (F1, R1 and F2, R2) were used for PCR amplification of the 2 DNA fragments that were ligated to form the chimeric constructs CH1 and CH2.
RECEPTOR-BINDING RESIDUES IN DBL DOMAINS 2559BLOOD, 15 MARCH 2005  VOLUME 105, NUMBER 6
in erythrocyte-binding assays (data not shown) indicating that it
is functional and correctly folded.
To identify fragments of F2 that retain receptor-binding activity,
recombinant F2 was treated with chymotrypsin and both full-length
F2 and proteolytic fragments of F2 were tested for binding to
glycophorin A in pull-down assays. Both F2 and proteolytic
fragments of F2 were incubated with glycophorin A to allow
binding. Antibodies to glycophorin A and protein A-coated beads
were then used to pull down glycophorin A-F2 fragment com-
plexes. Precipitated complexes were separated by SDS-PAGE, and
fragments of F2 that bound glycophorin A were detected by
Western blotting using rabbit sera raised against recombinant F2.
Full-length F2 as well as a 24-kDa proteolytic fragment of F2
bound glycophorin A in the pull-down assays (Figure 2). Incuba-
tion of F2 with BSA instead of glycophorin A did not result in
precipitation of F2 in pull-down assays (Figure 2). Moreover,
recombinant PvRII, the binding domain of P vivax Duffy-binding
protein, did not bind glycophorin A in the pull-down assays (data
not shown). The binding of F2 and the 24-kDa F2 fragment to
glycophorin A is thus specific. Protein N-terminal sequencing
revealed that the 24-kDa band starts with lysine 532 (K532), which
lies between cysteines C4 and C5 of EBA-175 (Figure 1).
Molecular mass considerations suggest that the 24-kDa fragment is
likely to span the region containing cysteines C5 to C12 of F2.
A series of deletion constructs were designed to express
truncated fragments of F2 on the surface of COS cells and test them
for binding to erythrocytes. All the deletion constructs include
cysteine C5 at the N-terminus and terminate either after cysteines
C14, C12, or C9 at the C-terminus. They are referred to as
F2(C5-C14), F2(C5-C12), and F2(C5-C9), respectively. Following
transfection, erythrocyte-binding assays were used to test the
binding of COS cells expressing deletion constructs of F2 to human
red cells. In control experiments, binding to neuraminidase-treated
human erythrocytes was examined. Constructs designed to express
region F2 or region II (F1F2) were used as positive controls.
Regions II (F1F2) and F2 bind normal human erythrocytes but do
not bind neuraminidase-treated human erythrocytes (Table 2). The
deletion constructs F2(C5-14), F2(C5-C12), and F2(C5-C9) also
bind human erythrocytes but not neuraminidase-treated human
erythrocytes (Table 2). COS cells expressing regions F2(C1-C14)
and F2(C5-C9) were also tested for binding to trypsin-treated
human erythrocytes. Trypsin cleaves glycophorin A but not glyco-
phorin B. Both the full-length domain F2(C1-C14) and F2(C5-C9)
did not bind trypsin-treated human erythrocytes that had lost
glycophorin A. Critical binding residues for sialic acid residues on
glycophorin A thus lie in the central region of F2 between cysteines
C5 and C9. The binding efficiency of region II (F1F2) is
significantly higher than the binding efficiency of region F2 alone.
Similarly, although F2(C5-C9) binds erythrocytes with correct
specificity, it binds poorly compared to regions II (F1F2), F2, and
F2(C5-C12) (Table 2).
Binding residues for CR1 lie in the central region of the DBL
domain of R29var1, the expressed var gene from rosetting P
falciparum strain R29
Red cells infected with P falciparum strain R29 bind CR1 on
uninfected erythrocytes to form rosettes.15 R29var1, the var gene
expressed in R29, has been identified.15 The functional receptor-
binding domain that binds CR1 has been mapped to the N-terminal
DBL domain, R29-DBL, of R29var1.15 R29-DBL contains
309 amino acids including 14 cysteines. Transfected COS cells
expressing R29-DBL on the surface bind CR1 on human erythro-
cytes.15 Here, we have determined if the receptor-binding residues
of R29-DBL map to the central region of R29-DBLa that is
equivalent to the central approximately 170-amino acid stretch
spanning C5 to C8 of PvRII and PkRII that contain binding
residues for the Duffy antigen.24
A multiple sequence alignment was performed to identify the
boundaries of the central region of R29-DBL that is homologous
to the C5-C8 regions of PvRII and PkRII (data not shown). The
multiple sequence alignment demonstrates that cysteines corre-
sponding to C11 and C12 of PvRII and PkRII are missing in
R29-DBL. In addition, 4 cysteines from the central region of
R29-DBL, C6, C8, C10, and C12, are not found in PvRII or
PkRII. A 233-amino acid stretch of R29-DBL that includes
cysteines C5 to C12 corresponds to the central C5 to C8 stretch of
PvRII and PkRII. A deletion construct, R29-DBL(C5-C12), was
used to express this central fragment of R29-DBL on the surface
of COS cells and test binding to normal human erythrocytes.
Binding to CR1-deficient human erythrocytes that express lower
levels of CR1 was tested in control experiments. Constructs
designed to express full-length R29-DBL and PvRII were also
Figure 2. Binding of recombinant F2 and chymotryptic F2 fragments to
glycophorin A in pull-down assays. Recombinant F2 was used in pull-down
assays with glycophorin A before and after treatment with chymotrypsin. Recombi-
nant F2 and chymotrypsin-treated F2 were incubated with glycophorin A to allow
binding. F2 fragments bound to glycophorin A were precipitated using a mouse
monoclonal antibody raised against glycophorin A and protein A-Sepharose. Bound
F2 fragments were separated by SDS-PAGE and detected by Western blotting using
rabbit sera raised against recombinant F2. MW indicates prestained molecular weight
markers shown in kDa; lane 1, full-length recombinant F2 used for pull-down assays;
lane 2, pull-down assay with recombinant F2 and glycophorin A; lane 3, pull-down
assay with chymotrypsin-treated F2 (incomplete proteolysis) and glycophorin A; lane
4, chymotrypsin-treated F2 (incomplete proteolysis) used for pull-down assay; lane 5,
control pull-down assay using recombinant F2 and BSA instead of glycophorin A; lane
6, full-length recombinant F2; lane 7, chymotrypsin-treated F2 (complete proteolysis);
lane 8, pull-down assay with chymotrypsin-treated F2 (complete proteolysis) and
glycophorin A.
Table 2. Binding of normal and neuraminidase-treated human
erythrocytes to deletion constructs of region F2 of EBA-175
Construct
Transfection
efficiency,
%
No. rosettes* Binding efficiency†
Normal Neu Normal Neu
Exp
1
Exp
2
Exp
1
Exp
2
Exp
1
Exp
2
Exp
1
Exp
2
Exp
1
Exp
2
F1  F2 10 25 101 161 0 0 7.0 11.0 0 0
F2(C1-C14) 6 33 62 67 0 0 1.5 7.4 0 0
F2(C5-C14) 9 31 51 19 0 0 1.7 1.9 0 0
F2(C5-C12) 5 28 48 31 0 0 1.0 3.0 0 0
F2(C5-C9) 15 30 8 9 0 0 0.5 1.0 0 0
Untransfected NA NA 0 0 0 0 0 0 0 0
Neu indicates neuraminidase-treated erythrocytes; NA, not applicable.
*The number of COS-7 cells with rosettes of bound erythrocytes was scored in 25
fields at  200 magnification. Data from 2 independent experiments are reported.
The number of rosettes observed was normalized for transfection efficiency of 20%
for both experiments. No rosettes were observed in the entire well where number of
rosettes is reported as zero.
†The binding efficiency is calculated as follows: % binding efficiency  no. of
COS cells with rosettes  100/total no. of COS cells.
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used as controls. PvRII binds both normal and CR1-deficient cells
with similar efficiency. In contrast, both R29-DBL and R29-
DBL(C5-C12) bind CR1-deficient erythrocytes poorly compared
to normal human erythrocytes (Table 3). The deletion construct
R29-DBL(C5-C12) and full length R29-DBL(C1-C14) thus
bind CR1 on human erythrocytes. The binding residues for CR1 lie
in the central region of R29-DBL in the amino acid stretch
containing cysteines C5 to C12 (Figure 1).
Binding residues for CSA lie in the central region of DBL
from FCR3varCSA
The DBL domain, FCR3-DBL, derived from the var gene,
FCR3varCSA, has been shown to bind CSA.21 FCR3-DBL
contains 302 amino acids including 10 cysteines. Multiple se-
quence alignment of FCR3-DBLwith PvRII and PkRII revealed
that the region spanning cysteines C5 to C8 of FCR3-DBL
corresponds to the C5 to C8 stretch of PvRII and PkRII24 (data not
shown). Full-length FCR3-DBL containing cysteines C1 to C10
(FCR3-DBL(C1-C10)) as well as deletion fragments containing
cysteines C5 to C10 (FCR3-DBL(C5-C10)) and cysteines C5 to
C8 (FCR3-DBL(C5-C8)) were expressed on the surface of
mammalian 293T cells and tested for binding to CSA. In control
experiments, binding was tested to CSB and CSC. FCR3-DBL(C1-
C10), FCR3-DBL(C5-C10), and FCR3-DBL(C5-C8) bound
CSA but not CSB or CSC (Table 4). The binding residues for CSA,
thus, lie in the central region of FCR3-DBL between cysteines C5
and C8 (Figure 1).
Mapping the region that contains binding residues for ICAM-1
within DBLC2 of JDP8Icvar
P falciparum field isolate JDP8 binds ICAM-1.22 The ICAM-1–
binding domain has been mapped to the DBLC2 domain of
JDP8Icvar, the var gene expressed in P falciparum JDP8.22 The
DBL and C2 domains of JDP8-DBLC2 contain 12 and 4
conserved cysteines, respectively. Neither JDP8-DBL nor JDP8-C2
bind ICAM-1 when expressed separately.22 Both JDP8-DBL and
JDP8-C2 are thus necessary for binding to ICAM-1. Here, we have
tested the ICAM-1–binding ability of chimeric constructs that
contain stretches from JDP8-DBLC2, which binds ICAM-1,
fused to stretches from a homologous DBLC2 domain, FCR3-
DBLC2, which does not bind ICAM-1 (Figure 3). The chimeric
construct, CH1, which contains JDP8-DBL fused to FCR3-C2,
does not bind ICAM-1 (Figure 3), indicating that the JDP8-C2
domain contains some contact residues that are critical for binding
to ICAM-1. Similarly, a chimeric construct, CH2, which contains
FCR3-DBL fused to JDP8-C2 does not bind ICAM-1 (Figure 3),
indicating that JDP8-C2 sequences are necessary but not sufficient
for binding to ICAM-1. Both DBL and C2 domains thus contain
binding residues for ICAM-1. Multiple sequence alignment of
JDP8-DBLC2 with PvRII and PkRII revealed that cysteines C5
of PvRII and PkRII correspond to cysteine C3 of JDP8-
DBLC224 (data not shown). Deletion constructs were used to
express truncated JDP8-DBLC2 domains on the surface of COS
cells and test binding to ICAM-1. JDP8-DBLC2(C3-C16) binds
ICAM-1 (Figure 3). JDP8-DBL(C3-C7), which does not contain
the C2 region, fails to bind ICAM-1 (Figure 3). Binding residues
for ICAM-1 thus lie in the region spanning cysteines C3-C16 of
JDP8-DBLC2.
Table 3. Binding of normal human erythrocytes and CR1-deficient human erythrocytes to deletion constructs of R29-DBL
Construct
Transfection
efficiency, %
No. rosettes* Binding efficiency, %†
Normal CR1-deficient Normal CR1-deficient
Exp 1 Exp 2 Exp 1 Exp 2 Exp 1 Exp 2 Exp 1 Exp 2
R29-DBL(C1-C14) 33 120 105 40 25 36 39 11 10
R29-DBL(C5-C12) 33 142 95 40 26 38 36 10 9
PvRII 60 217 144 204 153 56 55 53 50
Untransfected NA 0 0 0 0 0 0 0 0
*The number of COS-7 cells with rosettes of bound erythrocytes was scored in 25 fields at  200 magnification. Data from 2 independent experiments are reported.
Transfection efficiency for experiment 1 is shown. No rosettes were seen in entire well where number of rosettes is reported as zero.
†The binding efficiency is calculated as follows: % binding efficiency  no. of COS cells with rosettes  100/total no. of COS cells..
Table 4. Binding of CSA, CSB, and CSC to deletion constructs
of FCR3-DBL
Construct
Transfection efficiency,
%
Binding efficiency,
CSA, %*
Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3
FCR3-DBL(C1-C10) 64 64 74 60 60 57
FCR3-DBL(C5-C10) 63 60 65 62 62 64
FCR3-DBL(C5-C8) 61 65 67 67 61 67
Untransfected NA NA NA 0 0 0
*Transfected 293T cells were incubated with biotinylated CSA, CSB, and CSC.
FITC-conjugated streptavidin was used to detect binding of biotinylated CSA, CSB,
and CSC to 293T cells. Between 1500 and 2000 293T cells were scored. The number
of 293T cells that are fluorescent was determined. No fluorescent cells were seen in
entire well where binding efficiency is reported as zero. The binding efficiency was
calculated as follows: % binding efficiency  no. of fluorescent 293T cells  100/
total no. of 293T cells. None of the constructs bound CSB or CSC.
Figure 3. Binding of ICAM-1 to DBLC2 chimeric and deletion constructs.
Chimeric and deletion constructs based on the ICAM-1–binding DBLC2 domain
derived from JDP8Icvar (JDP8-DBLC2) and DBLC2 domain derived from
FCR3varCSA (FCR3-DBLC2), which does not bind ICAM-1, were expressed on
surface of COS-7 cells and tested for binding to ICAM-1. Transfection efficiency for
each construct is shown. Number of transfected COS-7 cells that bind ICAM1-Fc–
coated magnetic beads scored in 25 fields at  200 magnification and normalized to
transfection efficiency of 20% is shown. No binding was seen in the entire well where
zero binding is reported. Positions of cysteines are shown with sticks. ND indicates
not done.
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Discussion
Malaria parasites use DBL domains to bind diverse host receptors
to mediate interactions that are involved in 2 key pathogenic
processes, namely, red cell invasion and cytoadherence.1 Receptor-
binding domains of both EBPs, which mediate red cell invasion,
and PfEMP-1, which mediate cytoadherence, have been mapped to
DBL domains.1 It is important to understand how these conserved
cysteine-rich domains are able to bind such a diverse range of host
receptors. What is the underlying conserved architecture of DBL
domains and where do their receptor-binding pockets lie? A clear
understanding of the interaction of DBL domains with their
receptors may allow the development of novel strategies to inhibit
red cell invasion or reverse cytoadherence.
Phylogenetic analysis of DBL domains reveals that DBL
domains derived from EBPs group together.30,31 The PfEMP-1
DBL domains have diverged significantly from the EBP DBL
domains and cluster into at least 6 distinct sequence subtypes
designated , , , 	, 
, and X.30-32 DBL domains of EBPs contain
12 invariant cysteines. The first 10 cysteines from EBP DBL
domains can usually be identified in PfEMP-1 DBL domains,
although in some cases a subset of cysteines may be missing and
novel cysteines may appear. Interspersed between the cysteines are
conserved amino acid stretches that form type-specific homology
blocks that are flanked by hypervariable amino acid stretches. EBP
DBL domains display natural variation in sequence due to point
mutations but rarely display variation in length of amino acid
stretches between invariant cysteines.30 In contrast, PfEMP-1 DBL
domains display great divergence in both sequence and length even
among DBL domains of the same subtype.30 Despite the extent of
sequence diversity in DBL domains, it is predicted that due to the
presence of conserved cysteines and homology blocks between
invariant cysteines, DBL domains may have a common fold.30 As a
result the receptor-binding pockets may lie in the same region of
diverse DBL domains.
We have previously shown that critical binding residues for the
Duffy antigen lie in a central stretch of about 170 amino acids
spanning C5 to C8 of the prototypical DBL domains, PvRII and
PkRII.23,24 Here, we have tested whether the binding residues of
other DBL domains from EBPs and PfEMP-1 also lie in central
regions equivalent to the C5 to C8 stretch of PvRII and PkRII. We
have analyzed the interaction of DBL domain F2 from P falcipa-
rum EBA-175, which binds sialic acid on glycophorin A to mediate
invasion. Proteolytic cleavage of recombinant F2 using chymotryp-
sin followed by pull-down assays using glycophorin A identified a
24-kDa fragment starting with K532 of EBA-175 at the N-terminus
that retained binding activity. The position of the cleavage site
resulting in the functionally active 24-kDa fragment indicates that,
as previously seen for PvRII and PkRII,24 the amino acid stretch
spanning cysteines C1 to C4 is not required for binding. The use of
deletion constructs demonstrated that F2(C5-C9), which contains
cysteines C5 to C9, binds red cells with specificity. Binding
residues of DBL domain F2 thus lie in the central region as
previously seen for PvRII and PkRII. The deletion construct
F2(C5-C9) binds erythrocytes poorly compared to region II
(F1F2), region F2, and region F2(C5-C12). It is likely that
sequences outside the central region (C5-C9) play a role in the
binding affinity of region F2 either by influencing the folding of F2
or by contributing additional contact residues.
We have also mapped regions containing binding residues in
DBL domains derived from PfEMP-1 that mediate cytoadherence.
Binding sites were mapped in R29-DBL, which binds CR1,
FCR3-DBL, which binds CSA, and JDP8-DBLC2, which binds
ICAM-1. Multiple sequence alignments were performed to identify
central regions of these DBL domains that are equivalent to the C5
to C8 stretch of PvRII and PkRII24 (data not shown). Deletion
constructs were used to express the central regions of R29-DBL,
FCR3-DBL, and JDP8-DBLC2 on the surface of mammalian
cells and test them for binding to relevant receptors.
R29-DBL binds CR1 to mediate rosetting of P falciparum-
infected erythrocytes with uninfected erythrocytes.15 A deletion
construct, R29-DBL(C5-C12), which corresponds to the C5 to C8
stretch of PvRII and PkRII,24 binds erythrocytes with the same
specificity as full-length R29-DBL(C1-C14). Binding residues
for CR1 thus lie in the central region of R29-DBL as in case of
PvRII, PkRII, and F2 (Figure 1).
FCR3-DBL, which binds CSA, contains 14 cysteines.21 A
deletion construct, FCR3-DBL(C5-C8), which spans the central
region corresponding to the C5 to C8 stretch of PvRII and
PkRII,24 binds CSA with specificity. The binding residues for
CSA, thus, also lie in the central region of FCR3-DBL (Figure 1).
The ICAM-1–binding domain of JDP8Icvar has been mapped
to its DBLC2 domain.22 The C2 domain, which contains 4
conserved cysteines, is commonly found in association with DBL
domains of PfEMP-1.30 It has been previously shown that DBL
and C2 domains of JDP8Icvar do not bind ICAM-1 when expressed
separately indicating that both regions are required for binding.22
However, it was not clear if the C2 region plays a structural role
and is required for correct folding of the binding pocket or if C2
contains binding residues for ICAM-1. Here, we have used
chimeric constructs that contain regions from the ICAM-1–binding
JDP8-DBLC2 domain fused to regions from FCR3-DBLC2,
which does not bind ICAM-1, to distinguish between these
possibilities. The FCR3-DBL region contains the 12 conserved
cysteines (C1-C12) found in JDP8-DBL and FCR-C2 contains
the 4 conserved cysteines (C13-C16) found in JDP8-C2. The
chimeric constructs, CH1 and CH2, should thus be able to form the
correct disulfide linkages and fold correctly. The inability of CH1
and CH2 to bind ICAM-1 indicates that both DBL and C2 regions
of JDP8Icvar contain contact residues for ICAM-1. Deletion
constructs demonstrated that as observed for other DBL domains,
the N-terminal amino acid stretch spanning cysteines 1 to 4 of
JDP8-DBLC2 is not necessary for binding to ICAM-1.
In conclusion, we have mapped receptor-binding residues of
DBL domains from EBPs that bind the Duffy blood group antigen
and sialic acids on glycophorin A to mediate red cell invasion, as
well as DBL domains from PfEMP-1 that bind diverse cytoadher-
ence receptors such as CR1 to mediate rosetting, a binding
phenotype associated with severe malaria, and CSA, a cytoadher-
ence phenotype implicated in placental malaria. In each case, the
binding residues lie in the central regions of the DBL domains. The
central regions of DBL domain F2, R29-DBL, and FCR3-DBL
retain binding function when expressed on their own suggesting
that they constitute functional modules that can fold independently.
The flanking amino- and carboxyl-terminal regions of these DBL
domains are not essential for binding but may play a role in
modulating the fine specificity or affinity of the binding interaction.
A multidomain architecture with a central functional, receptor-
binding module was previously proposed for DBL domains based
on studies on the prototype DBL domains PvRII and PkRII from
PvDBP and PkDBP that bind the Duffy antigen.24 The studies
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presented here suggest that the model is valid for a wide range of
DBL domains from EBPs as well as from PfEMP-1 with diverse
binding specificity. The ICAM-1–binding DBLC2 domain ap-
pears to be a variation on this theme in that amino acids from both
the central region of DBL as well as the associated C2 region are
required for binding to ICAM-1.
Identification of the regions within DBL domains that contain
critical binding residues opens up the path toward understanding
the structure-function bases for their interaction with host recep-
tors. Efforts to determine the structures of DBL domains can now
focus on these regions, which contain the receptor-binding sites. In
addition, these regions may be targeted for site-directed mutagen-
esis to identify the contact residues that form the receptor-binding
pocket. A clear understanding of the receptor-ligand interactions
mediated by DBL domains may enable the development of novel
therapeutic or prophylactic strategies to block these interactions
and inhibit red cell invasion or reverse cytoadherence and protect
against malaria.
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